ASCO GU 2021 Prostate Cancer
- ASCO GU 2021: CTC Counts as a Biomarker of Prognosis and Response in Metastatic Castration-Resistant Prostate Cancer (mCRPC) from the CARD Trial
- ASCO GU 2021: Back to Basics in Personalization: Returning to PTEN
- ASCO GU 2021: 177Lu-PSMA-617 (LuPSMA) Versus Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer Progressing After Docetaxel: Updated Results Including Progression-Free Survival and Patient-Reported Outcomes (TheraP ANZUP 1603)
- ASCO GU 2021: Final Results from ACIS, a Randomized, Placebo-Controlled Double-Blind Phase 3 Study of Apalutamide and Abiraterone Acetate plus Prednisone (AAP) Versus AAP in Patients with Chemo-Naive Metastatic Castration-Resistant Prostate Cancer
- ASCO GU 2021: Biomarker Analysis from a Randomized Phase II Study of Olaparib with or Without Cediranib in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
ASCO GU 2021 Bladder Cancer
- ASCO GU 2021: Role of Definitive Local Therapy After Complete Clinical Response to Neoadjuvant Chemotherapy
- ASCO GU 2021: Optimal Radiologic Assessment After Systemic Therapy for Muscle-Invasive Bladder Cancer
- ASCO GU 2021: Patient Perspective on Newly Diagnosed Muscle-Invasive Bladder Cancer: What Do I Hope the Doctor Will Address?
- ASCO GU 2021: First Results from the Phase 3 CheckMate 274 Trial of Adjuvant Nivolumab vs Placebo in Patients Who Underwent Radical Surgery for High-Risk Muscle-Invasive Urothelial Carcinoma
- ASCO GU 2021: Phase II Clinical Study of Concurrent Durvalumab and Radiation Therapy (DUART) Followed by Adjuvant Durvalumab in Patients with Localized Urothelial Cancer of Bladder: Results for Primary Analyses and Survival. BTCRC-GU15-023
ASCO GU 2021 Kidney Cancer
- ASCO GU 2021: MK-6482 in Patients with Patients with Clear Cell Renal Cell Carcinoma: Discussion
- ASCO GU 2021: The CLEAR Study of Lenvatinib Plus Pembrolizumab or Everolimus vs Sunitinib and the SWOG 1500 Trial of Sunitinib, Cabozantinib, Crizotinib, and Savolitinib in Advanced Kidney Cancer: Discussion
- ASCO GU 2021: The Oral HIF-2 α Inhibitor MK-6482 in Patients with Advanced Clear Cell Renal Cell Carcinoma (RCC): Updated Follow-up of a Phase I/II Study
- ASCO GU 2021: Phase 3 Trial of Lenvatinib plus Pembrolizumab or Everolimus Versus Sunitinib Monotherapy as a First-Line Treatment for Patients with Advanced Renal Cell Carcinoma (CLEAR Study)
- ASCO GU 2021: Phase 2 Study of the Oral Hypoxia-Inducible Factor 2α (HIF-2α) Inhibitor MK-6482 in Combination with Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
ASCO GU 2021 Penile, Urethral, Testicular, and Adrenal Cancers
- ASCO GU 2021: Australia and New Zealand Outcomes of High-Dose Chemotherapy and Stem Cell Transplantation for Relapsed or Refractory Germ Cell Tumors from 1999 to 2019: Multicenter Registry-Based Study with ABMTRR
- ASCO GU 2021: Prediction Model for Brain Metastasis in Patients with Metastatic Germ-Cell Tumors Accounting for Size of Pulmonary Metastases
- ASCO GU 2021: Longer Follow-up Data of Circulating miR371a-3p Expression Across the Spectrum of Germ Cell Tumors
- ASCO GU 2021: Discussant: Results from the TRISST and SEMS Trials
- ASCO GU 2021: Comprehensive Genomic Profiling in Patients with Relapsed/Refractory Germ Cell Tumors
ASCO GU 2021 Press Releases
- ANZUP Reports A New Class of Effective Therapy for Men with Metastatic Castration-Resistant Prostate Cancer
- Weill Cornell Medicine Experts Presenting at 2021 ASCO GU
- Foundation Medicine and Its Collaborators Announce New Study Results Further Demonstrating the Clinical Utility of Blood-Based Comprehensive Genomic Profiling in Patients with Advanced Prostate Cancer
- Nivolumab in Combination with Cabozantinib Shows Sustained Survival and Response Rate Benefits as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma in the Phase 3 CheckMate -9ER Trial
- Janssen Announces Treatment with Apalutamide Significantly Improved Overall Survival in Patients with Metastatic Castration-Sensitive Prostate Cancer